GlobeNewswire

EnvoyAI Made Available to Over 200 UK Healthcare Locations

Share

LIVERPOOL, United Kingdom, June 10, 2019 (GLOBE NEWSWIRE) -- Advanced visualization and artificial intelligence (AI) technology provider, TeraRecon, today announced that it has reached agreement with Insignia Medical Systems to make its EnvoyAI™ platform available to Insignia’s vast PACS and Regional Image Sharing Platform (RISP) networks currently running in over 200 United Kingdom (U.K.) healthcare sites. 

EnvoyAI is the world's first medical imaging AI marketplace and interoperability platform, currently offering over 80 algorithms with 20 holding regulatory clearances in various global territories. It allows clinicians to experiment with its ever-growing number of commercial-ready and research-use AI products. Health systems can enter into one simple contractual agreement and run all algorithms on the EnvoyAI platform identically, interchangeably, and with immediate access.

Richard Dormer, Managing Director of Insignia, said “With access to EnvoyAI via the Insignia RISP and Insignia PACS systems, we make it possible for clinicians to work locally and to collaborate with AI innovations across entire U.K. regions. Insignia client locations are home to tens of thousands of clinicians that are now able to experience EnvoyAI and access its full range of artificial intelligence algorithms alongside the impressive Insignia PACS integration and workflow capabilities.”

The U.K. National Health Service has been making significant investments in the development and adoption of AI technologies, including algorithm creation and testing of novel AI-driven medical imaging workflows. TeraRecon has also made significant investments in AI technology including the EnvoyAI platform, the Northstar™ AI Results Explorer, and a sophisticated developer portal that is used by data scientists and AI companies to turn their AI projects into secure EnvoyAI-compatible image processing engines, accessible by a rapidly growing number of EnvoyAI key opinion leaders and clinical end-user installations.

“Even the most polished and proven new algorithms cannot deliver any impact without actually being incorporated into the clinical workflow so that they can be used. We provide a revolutionary new kind of AI technology platform which allows these algorithms to be accessed and run simultaneously, and to have their remarkable results directly incorporated into the electronic health record, the radiology PACS and even clinical decision support systems” said Jeff Sorenson, President and CEO of TeraRecon. He continued, “This partnership is one of the first of its kind to extend the reach of imaging AI far beyond the academic or research realm into the regional and community facilities that arguably need it most.”

TeraRecon technologies including the EnvoyAI platform, TeraRecon Northstar AI Results Explorer, and its flagship iNtuition™ advanced visualization solution, will be on display at the UK Imaging and Oncology Congress (Book a demo at UKIO) in Liverpool, England from June 10th – June 12th, 2019. Online demonstrations are available by contacting TeraRecon at info@terarecon.com.

About TeraRecon (www.terarecon.com) TeraRecon is a leader in medical advanced visualization and artificial intelligence solutions. Our flagship product, iNtuition, consistently leads the advanced visualization category of the industry’s leading independent technology analyst. The company continues to innovate ahead of customer demand and has most recently developed new sophisticated healthcare-focused artificial intelligence platform solutions unlike any in the world today. EnvoyAI was the recipient of the prestigious Aunt Minnie 2018 Best New Radiology Vendor award. TeraRecon’s Northstar AI Results Explorer is the first and only enterprise-wide solution capable of delivering AI imaging insights directly and interactively into the systems clinicians use every day. As a company with a 20-year history of innovation, TeraRecon’s mission is to continuously redefine medical advanced visualization and leverage artificial intelligence to improve patient care.

About Insignia (www.insigniamedical.co.uk) Insignia Medical Systems is the pioneering UK-based medical imaging provider offering technology-leading solutions. With over 18 years pedigree, Insignia has unrivalled experience in providing services that help improve the delivery of healthcare and outcomes for patients.

Press Inquiries US: 1-650-372-1100 | info@terarecon.com

TeraRecon, iNtuition, EnvoyAI, and Northstar are trademarks of TeraRecon, Inc.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality16.8.2019 17:17:00 CESTPress release

Expanded TAVR Indication to Younger, More Active Patients Signals Groundbreaking Shift in the Future Treatment of Heart Valve Disease DUBLIN, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) system for patients with symptomatic severe native aortic stenosis who are at a low risk of surgical mortality. The low-risk patient population is the final surgical risk category to be approved for this minimally invasive alternative to open-heart surgical valve replacement (SAVR) and includes patients who may be younger and more active than higher-risk patients. The expanded indication approval is based on randomized clinical data from the global, prospective, multi-center Evolut Low Risk Trial, which evaluated three valve generations (CoreValve™, Evolut™ R, and Evolut™ PRO valves) in more than 1,400 patients. The data showed TAVR to have an excellent safety prof

Acacia Pharma Group plc - Issue of Equity on Exercise of Options16.8.2019 16:39:00 CESTPress release

Cambridge, UK and Indianapolis, US – 16 August 2019: Acacia Pharma Group plc (the "Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 106,997 Ordinary Shares of £0.02 each (the “New Ordinary Shares”) to trading on Euronext Brussels ("Admission") to satisfy the exercise of options granted under the Company’s [Enterprise Management Incentive Share Option Plan]. The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue. Following issue of the New Ordinary Shares, the Company's total issued share capital will consist of 53,442,417 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of votin

Conditions for Riksbank Bid Procedures Sek Bonds16.8.2019 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2019-08-22 Maturity date Loan ISIN code Coupon Volume, SEK million 2025-05-12 1058 SE0005676608 2.50 % 500 +/- 250 2029-11-12 1061 SE0011281922 0.75 % 500 +/ -250 Settlement date 2019-08-26 Bids have to be entered by 10.00 on AUG 22, 2019 Highest permitted bid volume: 500 SEK million in issue SGB 1058 and 500 SEK million in issue SGB 1061 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON AUG 22, 2019 For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

Correction: Prosafe SE: Publication of Information Memorandum16.8.2019 15:05:00 CESTPress release

Correction: the Information Memorandum was not attached to the previous announcement, and has now been attached. Not for release, publication or distribution, in whole or in part, in or into any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. Reference is made to announcement of 3 June 2019 concerning the merger agreement between Prosafe SE ("Prosafe", OSE ticker PRS) and Floatel International Ltd ("Floatel"). Pursuant to section 3.5 of the Oslo Stock Exchange Continuing Obligations for listed companies, Prosafe has today published an information memorandum in respect of the merger. A copy of the information memorandum is available on www.newsweb.no and on Prosafe's website along with relevant financial reports at the following link: https://www.prosafe.com/information-memorandum/category1096.html Stavanger, 16 August 2019 Prosafe SE For further questions, please contact: Glen Ole Rødland, Chairman of Prosafe: + 47 907 41 662 Jesper K

Avance Gas Holding Ltd - Invitation to Earnings Release Audio Webcast for the Second Quarter of 201916.8.2019 14:38:00 CESTPress release

Bermuda, 16 August 2019 - Avance Gas Holding Ltd (OSE: "AVANCE"), will on Thursday 22 August 2019 release its unaudited results for the second quarter of 2019. In connection with the earnings release, an audio webcast and conference call will be held at 15:00 (CET). The webcast can be accessed at Avance Gas' website www.avancegas.com. Dial in details are +44 (0) 2071 928 000 (UK and International), +1 631 510 7495 (US) or +47 23 96 02 64 (Norway). Please quote the passcode: 3835678. Phone lines will open 10 minutes before the conference call. For further queries, please contact: Peder C. G. Simonsen CFO Tel: +47 22 00 48 15 Email: p.simonsen@avancegas.com ABOUT AVANCE GAS Avance Gas Holding Ltd operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGCs), operating a fleet of 14 modern VLGC. For more information about Avance Gas, please visit: www.avancegas.com This i